Summary

Patients with heart failure (HF) often remain symptomatic and have a poor prognosis despite treatment with existing therapies [Cleland JG et al. Lancet 2011]. Several new therapeutic options are currently emerging for HF, including direct renin inhibitors, neprilysin inhibitors, selective If channel inhibitors, cardiac myosin activators, vasopressin receptor antagonists, and phosphodiesterase type 5 inhibitors. This article discusses clinical trial data for direct renin inhibitors and neprilysin inhibitors.